Comparison of Seven Sarcopenia Screening Tools in Older Type 2 Diabetes Patients Using Four Diagnostic Criteria

基于四种诊断标准对七种肌少症筛查工具在老年2型糖尿病患者中的应用进行比较

阅读:5

Abstract

OBJECTIVES: To compare the diagnostic accuracy of seven sarcopenia screening tools against four international guidelines. METHODS: This cross-sectional study recruited 330 Chinese older patients from a tertiary hospital. Sarcopenia was diagnosed based on muscle mass, strength, and physical performance using four guidelines: the Asian Working Group for Sarcopenia (AWGS) 2019 consensus, The updated version of the European Working Group on Sarcopenia in Older People (EWGSOP2), Foundation for the National Institutes of Health Sarcopenia Project (FNIH), and the International Working Group on Sarcopenia (IWGS). Seven screening tools included: SARC-F, MSRA-7, MSRA-5, Calf Circumference (CC), Finger-ring Test, SARC-CalF, and Ishii Score. Diagnostic accuracy was assessed using sensitivity, specificity, and receiver operating characteristic (ROC) curve analysis, including area under the curve (AUC). RESULTS: This study enrolled 330 older adults with type 2 diabetes, including 172 women and 158 men, with a mean age of 68.35 ± 6.32 years. Sarcopenia prevalence ranged from 7.58% to 27.27%. The Ishii Score showed the highest accuracy for screening sarcopenia in older patients with T2DM. Under the 2019 consensus of the Asian Working Group for Sarcopenia criteria, sensitivity ranged from 13.33% (SARC-F) to 80.00% (Ishii Score), and specificity ranged from 27.92% (MSRA-7) to 91.67% (SARC-F). AUCs ranged from 0.51 (MSRA-5) to 0.79 (Ishii Score). In subgroup analyses, the Ishii Score also demonstrated the highest AUC values in men (0.79) and in women (0.83). The performance of tools varied against other three golden standards, with sensitivity (8.00%-98.04%), specificity (27.21%-91.67%), and AUC (0.51-0.88). CONCLUSIONS: The Ishii score demonstrated the highest overall diagnostic accuracy for sarcopenia screening. CC may be ideal for rapid screening, while SARC-F suits confirmatory testing. Further validation of these tools in diverse settings is needed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。